{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:53:30Z","timestamp":1790268810514,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Education and Science, Poland","award":["ST3 02-0003\/07\/518"],"award-info":[{"award-number":["ST3 02-0003\/07\/518"]}]},{"name":"Ministry of Education and Science, Poland","award":["ST3 02-0003\/07\/518"],"award-info":[{"award-number":["ST3 02-0003\/07\/518"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this work, we investigated the antitubercular properties of Ciprofloxacin derivatives conjugated with menthol and thymol moieties. For the sixteen derivatives, we established minimal inhibitory concentrations (MIC) using isolates of <jats:italic>Mycobacterium tuberculosis<\/jats:italic> that were resistant or susceptible to other antibiotics. For the most potent compound 1\u2010cyclopropyl\u20106\u2010fluoro\u20107\u2010{4\u2010[6\u2010((1R,2S,5R)\u20102\u2010isopropyl\u20105\u2010methylcyclohexyloxy)\u20106\u2010oxohexyl]piperazin\u20101\u2010yl}\u20104\u2010oxo\u20101,4\u2010dihydroquinoline\u20103\u2010carboxylic acid (<jats:bold>6<\/jats:bold>), we determined fractional inhibitory concentration index (FICI) values to confirm antibacterial susceptibility and synergistic effects with other reference drugs. In addition, chromatographic studies of all the derivatives demonstrated a significant three to four-fold increase in lipophilicity and affinity to phospholipids compared to Ciprofloxacin. Finally, we conducted structure-based studies of the investigated compounds using molecular docking and taking into account protein target mutations associated with fluoroquinolone resistance. In summary, our findings indicate that the investigated compounds possess tuberculostatic properties, with some showing similar or even better activity against resistant strains compared to reference drugs. Increased lipophilicity and affinity to phospholipids of the new derivatives can offer several advantages for new drug candidates, beyond just improved cell membrane penetration. However, further studies are needed to fully understand their safety, efficacy, and mechanism of action.<\/jats:p>","DOI":"10.1038\/s41598-023-43708-4","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T13:02:39Z","timestamp":1695906159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Menthol- and thymol-based ciprofloxacin derivatives against Mycobacterium tuberculosis: in vitro activity, lipophilicity, and computational studies"],"prefix":"10.1038","volume":"13","author":[{"given":"Daniel","family":"Szulczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Wozi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Koli\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kmiecik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"G\u0142ogowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Augustynowicz-Kope\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142 A.","family":"Dobrowolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Roszkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Struga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzesimir","family":"Ciura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"43708_CR1","unstructured":"Global tuberculosis report 2022. https:\/\/www.who.int\/publications-detail-redirect\/9789240061729."},{"key":"43708_CR2","unstructured":"WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online: https:\/\/covid19.who.int\/."},{"key":"43708_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41586-018-0327-4","volume":"559","author":"M De Rycker","year":"2018","unstructured":"De Rycker, M., Baraga\u00f1a, B., Duce, S. & Gilbert, I. H. Challenges and recent progress in drug discovery for tropical diseases. Nature 559, 498\u2013506 (2018).","journal-title":"Nature"},{"key":"43708_CR4","doi-asserted-by":"publisher","first-page":"7489","DOI":"10.1021\/acs.jmedchem.2c00227","volume":"65","author":"GC Fernandes","year":"2022","unstructured":"Fernandes, G. C., Thompson, A., Castagnolo, D., Denny, W. A. & Santos, J. L. D. Tuberculosis drug discovery: Challenges and new horizons. J. Med. Chem. 65, 7489\u20137531 (2022).","journal-title":"J. Med. Chem."},{"key":"43708_CR5","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1128\/AAC.00695-11","volume":"55","author":"H Takiff","year":"2011","unstructured":"Takiff, H. & Guerrero, E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob. Agents Chemother. 55, 5421\u20135429 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"43708_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.5588\/ijtld.12.0277","volume":"16","author":"J Grosset","year":"2012","unstructured":"Grosset, J., Singer, T. & Bishai, W. R. New drugs for the treatment of tuberculosis: Hope and reality [State of the art series. New tools. Number 2 in the series]. Int. J. Tuberc. Lung Dis. 16, 1005\u20131014 (2012).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"43708_CR7","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/S0960-894X(03)00376-7","volume":"13","author":"RJ Kerns","year":"2003","unstructured":"Kerns, R. J. et al. Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus. Bioorg. Med. Chem. Lett. 13, 2109\u20132112 (2003).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"43708_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1556\/1886.2021.00021","volume":"12","author":"M Heidary","year":"2022","unstructured":"Heidary, M. et al. Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment. Eur. J. Microbiol. Immunol. (Bp) 12, 1\u201317 (2022).","journal-title":"Eur. J. Microbiol. Immunol. (Bp)"},{"key":"43708_CR9","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00706-018-2215-x","volume":"149","author":"J Fedorowicz","year":"2018","unstructured":"Fedorowicz, J. & S\u0105czewski, J. Modifications of quinolones and fluoroquinolones: Hybrid compounds and dual-action molecules. Monatshefte Chem. 149, 1199\u20131245 (2018).","journal-title":"Monatshefte Chem."},{"key":"43708_CR10","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.3390\/ijms23126600","volume":"23","author":"T Szostek","year":"2022","unstructured":"Szostek, T. et al. Design and synthesis of menthol and thymol derived ciprofloxacin: Influence of structural modifications on the antibacterial activity and anticancer properties. Int. J. Mol. Sci. 23, 6600 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"43708_CR11","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1128\/AAC.49.6.2474-2478.2005","volume":"49","author":"D Trombetta","year":"2005","unstructured":"Trombetta, D. et al. Mechanisms of antibacterial action of three monoterpenes. Antimicrob. Agents Chemother. 49, 2474\u20132478 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"43708_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3389\/fchem.2019.00653","volume":"7","author":"DJ Walsh","year":"2019","unstructured":"Walsh, D. J., Livinghouse, T., Goeres, D. M., Mettler, M. & Stewart, P. S. Antimicrobial activity of naturally occurring phenols and derivatives against biofilm and planktonic bacteria. Front. Chem. 7, 653 (2019).","journal-title":"Front. Chem."},{"key":"43708_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jpba.2018.07.010","volume":"159","author":"AH Rageh","year":"2018","unstructured":"Rageh, A. H., Atia, N. N. & Abdel-Rahman, H. M. Application of salting-out thin layer chromatography in computational prediction of minimum inhibitory concentration and blood-brain barrier penetration of some selected fluoroquinolones. J. Pharm. Biomed. Anal. 159, 363\u2013373 (2018).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"43708_CR14","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1039\/C4AY02203C","volume":"7","author":"U Hubicka","year":"2015","unstructured":"Hubicka, U., \u017buromska-Witek, B., Komsta, \u0141 & Krzek, J. Lipophilicity study of fifteen fluoroquinolones by reversed-phase thin-layer chromatography. Anal. Methods 7, 3841\u20133848 (2015).","journal-title":"Anal. Methods"},{"key":"43708_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejps.2012.04.022","volume":"47","author":"G V\u00f6lgyi","year":"2012","unstructured":"V\u00f6lgyi, G., Vizser\u00e1lek, G., Tak\u00e1cs-Nov\u00e1k, K., Avdeef, A. & Tam, K. Y. Predicting the exposure and antibacterial activity of fluoroquinolones based on physicochemical properties. Eur. J. Pharm. Sci. 47, 21\u201327 (2012).","journal-title":"Eur. J. Pharm. Sci."},{"key":"43708_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejps.2007.04.003","volume":"31","author":"F Barbato","year":"2007","unstructured":"Barbato, F., Cirocco, V., Grumetto, L. & La Rotonda, M. I. Comparison between immobilized artificial membrane (IAM) HPLC data and lipophilicity in n-octanol for quinolone antibacterial agents. Eur. J. Pharm. Sci. 31, 288\u2013297 (2007).","journal-title":"Eur. J. Pharm. Sci."},{"key":"43708_CR17","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.3390\/ijms20215288","volume":"20","author":"K Ciura","year":"2019","unstructured":"Ciura, K. et al. Lipophilicity determination of quaternary (fluoro) quinolones by chromatographic and theoretical approaches. Int. J. Mol. Sci. 20, 5288 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"43708_CR18","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3390\/pr8091148","volume":"8","author":"K Ciura","year":"2020","unstructured":"Ciura, K. et al. Affinity of fluoroquinolone-safirinium dye hybrids to phospholipids estimated by IAM-HPLC. Processes 8, 1148 (2020).","journal-title":"Processes"},{"key":"43708_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jpba.2016.04.009","volume":"130","author":"K Valko","year":"2016","unstructured":"Valko, K. Lipophilicity and biomimetic properties measured by HPLC to support drug discovery. J. Pharm. Biomed. Anal. 130, 35\u201354 (2016).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"43708_CR20","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1073\/pnas.1525047113","volume":"113","author":"TR Blower","year":"2016","unstructured":"Blower, T. R., Williamson, B., Kerns, R. D. & Berger, J. M. Crystal structure and stability of gyrase\u2013fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. 113, 1706\u20131713 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"43708_CR21","doi-asserted-by":"crossref","unstructured":"Woods, G. L. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. NCBI Bookshelf http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544374\/ (2011).","DOI":"10.1128\/9781555816728.ch73"},{"key":"43708_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/JCM.36.2.362-366.1998","volume":"36","author":"SG Franzblau","year":"1998","unstructured":"Franzblau, S. G. et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar blue assay. J. Clin. Microbiol. 36, 362\u2013366 (1998).","journal-title":"J. Clin. Microbiol."},{"key":"43708_CR23","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1021\/jm2008826","volume":"54","author":"F Reck","year":"2011","unstructured":"Reck, F. et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: Broad-spectrum antibacterial agents with reduced hERG activity. J. Med. Chem. 54, 7834\u20137847 (2011).","journal-title":"J. Med. Chem."},{"key":"43708_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52, 1 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"43708_CR25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/jac\/dkr566","volume":"67","author":"F Maruri","year":"2012","unstructured":"Maruri, F. et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother. 67, 819\u2013831 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"43708_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/cpbi.3","volume":"54","author":"B Webb","year":"2016","unstructured":"Webb, B. & Sali, A. Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinf. 54, 5\u20136 (2016).","journal-title":"Curr. Protoc. Bioinf."},{"key":"43708_CR27","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."},{"key":"43708_CR28","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1021\/cg901565q","volume":"10","author":"S Mahapatra","year":"2010","unstructured":"Mahapatra, S., Venugopala, K. N. & Row, T. N. G. A device to crystallize organic solids: Structure of ciprofloxacin, midazolam, and ofloxacin as targets. Cryst. Growth Des. 10, 1866\u20131870 (2010).","journal-title":"Cryst. Growth Des."},{"key":"43708_CR29","doi-asserted-by":"publisher","first-page":"o2773","DOI":"10.1107\/S160053681103707X","volume":"67","author":"J Qian","year":"2011","unstructured":"Qian, J., Gu, J., Shen, J., Hu, X. & Wu, S.-X. Moxifloxacinium chloride monohydrate. Acta Crystallogr. Sect. E-Struct. Rep. Online 67, o2773\u2013o2774 (2011).","journal-title":"Acta Crystallogr. Sect. E-Struct. Rep. Online"},{"key":"43708_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1524\/ncrs.2009.224.14.247","volume":"224","author":"L-C Yu","year":"2009","unstructured":"Yu, L.-C., Xia, Y. & Liu, S. Crystal structure of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyll- piperazinyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride, [C19H23FN3O4]Cl. Z. Kristallogr. New Cryst. Struct. 224, 247\u2013248 (2009).","journal-title":"Z. Kristallogr. New Cryst. Struct."},{"key":"43708_CR31","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1021\/acs.cgd.8b00363","volume":"18","author":"JTJ Freitas","year":"2018","unstructured":"Freitas, J. T. J., De Melo, C. C., Viana, O. M. M. S., Ferreira, F. F. & Doriguetto, A. C. Crystal structure of levofloxacin anhydrates: A high-temperature powder X-ray diffraction study versus crystal Structure prediction. Cryst. Growth Des. 18, 3558\u20133568 (2018).","journal-title":"Cryst. Growth Des."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43708-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43708-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43708-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T12:24:08Z","timestamp":1700483048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43708-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43708"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43708-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"24 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16328"}}